Insider Selling: Veracyte (NASDAQ:VCYT) Director Sells 10,000 Shares of Stock

Posted by Francis Steltz on May 22nd, 2026

Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) Director Robert Epstein sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $44.01, for a total transaction of $440,100.00. Following the transaction, the director owned 52,446 shares in the company, valued at $2,308,148.46. The trade was a 16.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Veracyte Trading Down 0.4%

Shares of NASDAQ:VCYT traded down $0.16 during trading on Friday, hitting $45.03. 1,168,043 shares of the stock were exchanged, compared to its average volume of 924,328. The company has a fifty day moving average price of $34.65 and a two-hundred day moving average price of $38.59. The company has a market cap of $3.59 billion, a PE ratio of 41.31 and a beta of 1.89. Veracyte, Inc. has a 12-month low of $22.61 and a 12-month high of $50.71.

Veracyte (NASDAQ:VCYT – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.18. The firm had revenue of $139.07 million during the quarter, compared to the consensus estimate of $130.36 million. Veracyte had a return on equity of 9.07% and a net margin of 16.25%.Veracyte’s quarterly revenue was up 21.5% on a year-over-year basis. During the same period last year, the business posted $0.31 EPS. Equities research analysts anticipate that Veracyte, Inc. will post 1.28 earnings per share for the current fiscal year.

Institutional Trading of Veracyte

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Veracyte by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 8,504,088 shares of the biotechnology company’s stock worth $291,945,000 after purchasing an additional 403,737 shares during the last quarter. Artisan Partners Limited Partnership raised its position in shares of Veracyte by 16.6% in the third quarter. Artisan Partners Limited Partnership now owns 7,370,467 shares of the biotechnology company’s stock valued at $253,028,000 after buying an additional 1,048,692 shares during the last quarter. ARK Investment Management LLC lifted its stake in shares of Veracyte by 17.5% during the third quarter. ARK Investment Management LLC now owns 4,465,775 shares of the biotechnology company’s stock valued at $153,310,000 after buying an additional 665,686 shares during the period. State Street Corp lifted its stake in shares of Veracyte by 3.8% during the fourth quarter. State Street Corp now owns 4,360,913 shares of the biotechnology company’s stock valued at $183,594,000 after buying an additional 161,239 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Veracyte by 3.2% during the third quarter. Dimensional Fund Advisors LP now owns 3,118,166 shares of the biotechnology company’s stock worth $107,042,000 after acquiring an additional 95,664 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have recently issued reports on VCYT. Morgan Stanley cut their price target on Veracyte from $48.00 to $37.00 and set an “underweight” rating for the company in a research note on Thursday, March 5th. Guggenheim dropped their target price on shares of Veracyte from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday, March 30th. Needham & Company LLC restated a “buy” rating and set a $48.00 target price on shares of Veracyte in a research report on Wednesday, April 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Veracyte in a report on Friday, March 27th. Finally, Jefferies Financial Group started coverage on shares of Veracyte in a research report on Monday, April 13th. They issued a “buy” rating and a $45.00 price target on the stock. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $44.83.

Read Our Latest Report on VCYT

Veracyte Company Profile

(Get Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.